Oncotalks hematology videos and news

ASH 2018 - Francesco Passamonti, MD, Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly

Francesco Passamonti, MD from the Dipartimento di Medicina e Chirurgia, Università dell'Insubria, Varese, Italy is commenting on:

Ruxolitinib for the Treatment of Inadequately Controlled Polycythemia Vera without Splenomegaly: 156-Week Follow-up from the Phase 3 Response-2 Study

https://ash.confex.com/ash/2018/webprogram/Paper115350.html

0119JAK1106215

Related items

Moshe Mittelman, MD, PhD; Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)​

Moshe Mittelman, MD, PhD; Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)​

Moshe Mittelman, MD, PhD from the Tel Aviv University, Tel Aviv, Israel is commenting on the abstract: Long-Term Durability of Eltrombopag Clinical Benefit for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia (ASPIRE Part 3)Blood (2019) 134 (Supplement_1): 3740.https://doi.org/10.1182/blood-2019-130309
ASH , Latvia , Lithuania , Estonia , Albania
00:07:06
Sophie Servais, MD; Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study

Sophie Servais, MD; Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study

Sophie Servais, MD from the Université de Liège, Liège, Belgium is commenting on the abstract: Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective StudyBlood (2019) 134 (Supplement_1): 37.https://doi.org/10.1182/blood-2019-129992
ASH , Lithuania , Albania
00:03:30
Srdan Verstovsek, MD, PhD; US Optum Database Study in Polycythemia Vera Patients

Srdan Verstovsek, MD, PhD; US Optum Database Study in Polycythemia Vera Patients

Srdan Verstovsek, MD, PhD from the MD Anderson Cancer Center, Houston, VS is commenting on the abstract: US Optum Database Study in Polycythemia Vera Patients: Thromboembolic Events (TEs) with Hydroxyurea (HU) Vs Ruxolitinib Switch Therapy and Machine-Learning Model to Predict Incidence of Tes and HU FailureBlood (2019) 134 (Supplement_1): 1659.https://doi.org/10.1182/blood-2019-126410
ASH , Lithuania , Albania
00:05:10